CLINICAL SIGNIFICANCE OF DETECTION OF EGFR AND KRAS MUTATIONS IN PLASMA/PLEURAL EFFUSION IN PATIENTS WITH ADVANCED NSCLC

被引：0

作者：

Chen, Zhengtang ^{[1
]}

Sun, Jie ^{[1
]}

Ming, Hua ^{[1
]}

Sun, Jianguo ^{[1
]}

Wang, Xinxin ^{[1
]}

Peng, Lina ^{[1
]}

机构：

[1] Third Mil Med Univ, Xinqiao Hosp, Inst Canc, Chongqing, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷

关键词：

NSCLC; EGFR/KRAS mutation; tyrosine kinase inhibitor; pyrosequencing;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.06-003

引用

页码：S781 / S782

页数：2

共 50 条

[41] Dominance of EGFR and Insignificant KRAS Mutations in Prediction of Tyrosine-kinase Therapy for NSCLC Patients Stratified by Tumor Subtype and Smoking Status [J].

Pesek, Milos ;

Benesova, Lucie ;

Belsanova, Barbora ;

Mukensnabl, Petr ;

Bruha, Frantisek ;

Minarik, Marek .

ANTICANCER RESEARCH, 2009, 29 (07) :2767-2773

[42] Detection of EGFR Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, PNAClamp, and Digital PCR [J].

Siggillino, Annamaria ;

Ulivi, Paola ;

Pasini, Luigi ;

Reda, Maria Sole ;

Chiadini, Elisa ;

Tofanetti, Francesca Romana ;

Baglivo, Sara ;

Metro, Giulio ;

Crino, Lucio ;

Delmonte, Angelo ;

Minotti, Vincenzo ;

Roila, Fausto ;

Ludovini, Vienna .

DIAGNOSTICS, 2020, 10 (12)

[43] Characterization of KRAS Mutations in Black Patients with NSCLC at an Urban Academic Medical Center [J].

Dressler, D. ;

Fuchs, J. R. ;

Menon, S. V. ;

Hewlett, M. P. ;

Katam, N. ;

Gurley, M. ;

Chae, Y. K. ;

Boumber, Y. ;

Mohindra, N. ;

Vakkalagadda, C. V. ;

Patel, J. D. .

JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) :S486-S487

[44] EGFR AND K-RAS MUTATIONS IN JAPANESE PATIENTS WITH RESECTED NSCLC [J].

Shiina, Takayuki ;

Saito, Gaku ;

Ushiyama, Toshiki ;

Toishi, Masayuki ;

Hamanaka, Kazutoshi ;

Kurai, Makoto ;

Takasuna, Keiichiro ;

Kondo, Ryoichi ;

Yoshida, Kazuo ;

Amano, Jun .

JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) :S1492-S1493

[45] Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment [J].

Linardou, Helena ;

Kotoula, Vassiliki ;

Kouvatseas, George ;

Mountzios, Giannis ;

Karavasilis, Vasilios ;

Samantas, Epaminondas ;

Kalogera-Fountzila, Anna ;

Televantou, Despina ;

Papadopoulou, Kyriaki ;

Mavropoulou, Xanthipi ;

Daskalaki, Emily ;

Zaramboukas, Thomas ;

Efstratiou, Ioannis ;

Lampaki, Sofia ;

Rallis, Grigorios ;

Res, Eleni ;

Syrigos, Konstantinos N. ;

Kosmidis, Paris A. ;

Pectasides, Dimitrios ;

Fountzilas, George .

CANCER GENOMICS & PROTEOMICS, 2019, 16 (06) :531-541

[46] Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations [J].

Hayashi, Hidetoshi ;

Nadal, Ernest ;

Gray, Jhanelle E. ;

Ardizzoni, Andrea ;

Caria, Nicola ;

Puri, Tarun ;

Grohe, Christian .

CLINICAL LUNG CANCER, 2022, 23 (01) :E69-E82

[47] Possibilities of Overcoming Resistance to Osimertinib in NSCLC Patients with Mutations in the EGFR Gene [J].

Nicos, Marcin ;

Sroka-Bartnicka, Anna ;

Kalinka, Ewa ;

Krawczyk, Pawel .

CANCERS, 2025, 17 (04)

[48] To Investigate the Prognostic Factors and the Significance of TKI in Advanced NSCLC with Wild-Type EGFR [J].

Jiang, D. ;

Yu, Q. ;

Zhang, X. ;

Huang, F. ;

Li, Y. ;

Jin, H. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) :S1053-S1053

[49] LUNG CANCER Using ctDNA to track EGFR and KRAS mutations in advanced-stage disease [J].

Rosell, Rafael ;

Karachaliou, Niki .

NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (07) :401-402

[50] PREDICTIVE VALUE OF KRAS AND BRAF MUTATIONS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH CHEMOTHERAPY [J].

Dingemans, Anne-Marie ;

Smit, Egbert F. ;

Heideman, Danielle ;

Mellema, Wouter ;

Derks, Jules ;

Van, Robertjan Suylen ;

Thunnissen, Erik .

JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) :S1044-S1044

← 1 2 3 4 5 →